45.40
0.10 (0.22%)
| Penutupan Terdahulu | 45.30 |
| Buka | 45.28 |
| Jumlah Dagangan | 1,767,890 |
| Purata Dagangan (3B) | 3,579,770 |
| Modal Pasaran | 16,037,530,624 |
| Harga / Jualan (P/S) | 15.93 |
| Harga / Buku (P/B) | 3.45 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Aug 2025 |
| Margin Keuntungan | -147.36% |
| Margin Operasi (TTM) | -26.77% |
| EPS Cair (TTM) | -3.55 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 246.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.13% |
| Nisbah Semasa (MRQ) | 2.54 |
| Aliran Tunai Operasi (OCF TTM) | -679.51 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -689.60 M |
| Pulangan Atas Aset (ROA TTM) | -9.09% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | EVEREST MED | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.38 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| EVEREST MED | 16 B | - | - | 3.45 |
| BEONE MEDICINES | 297 B | - | 636.13 | 8.80 |
| HENLIUS | 35 B | - | 38.59 | 10.07 |
| INNOCARE | 34 B | - | - | 3.34 |
| ASCENTAGE-B | 24 B | - | - | 30.37 |
| AKESO | 111 B | - | - | 15.36 |
|
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.57% |
| % Dimiliki oleh Institusi | 33.61% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |